ATRA
Atara Biotherapeutics, Inc.
Atara Biotherapeutics (ATRA) Q2 2026 earnings
Published Aug 12, 2026
AI summary
- Revenue $630K, down 96% from $17.6M a year ago.
- GAAP EPS −$0.32 missed the −$0.25 consensus by $0.07, down from $0.19 a year ago.
- Atara reported second quarter 2026 revenue of $0.6 million, down from $17.6 million in the same period last year.
- The company recorded a net loss of $4.8 million, or $0.32 per share, compared to net income in the prior year.
- Revenue decline was primarily due to the accelerated recognition of deferred revenue in 2025.
Results vs analyst consensus
Revenue
Reported
$630K
Consensus not captured before release
−96% YoY
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.32
Consensus −$0.25
Missed by $0.07GAAP EPS: −$0.32
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- Revenue decreased significantly year-over-year due to the timing of deferred revenue recognition.
- The company reported a net loss for the quarter compared to net income in the prior year period.
Read original report
Source: Atara Biotherapeutics, Inc. press release · SEC Form 8-K exhibit 99.1